Epione allows physicians to treat inoperable tumors that are particularly difficult to reach, due to their size or their location, at an early stage, in a simple and effective way
French medical robotics company Quantum Surgical has obtained market authorization from the National Medical Products Administration (NMPA) for the use and commercialization of its Epione robot in China. Epione enables early and minimally invasive treatment of abdominal tumors. Nearly 610,000 new cases are diagnosed in China each year.
Quantum Surgical’s flagship product, the Epione robotic platform, is dedicated to the curative treatment of cancers. Epione allows physicians to treat inoperable tumors that are particularly difficult to reach, due to their size or their location, at an early stage, in a simple and effective way.
Epione can be used to treat abdominal tumors (including the liver, kidneys, and pancreas) and over 200 patients have already been treated in France and the United States.
The NMPA market authorization allows for offering this innovative, better targeted, and minimally invasive treatment to new patients in China, where nearly 610,000 new cases of abdominal cancers are diagnosed each year.
“Thanks to the NMPA market authorization, we are very excited to be able to offer our Epione solution to interventional oncologists in China. This is an important step that will provide Chinese patients with an innovative and minimally invasive treatment to treat their abdominal tumors at an early stage, while improving their comfort” says Bertin Nahum, President and Co-founder of Quantum Surgical.
“The NMPA market authorization confirms the effectiveness of Epione and, above all, the relevance of its deployment in China, where nearly 610,000 cases of abdominal cancers are diagnosed each year” explains Laetitia Messner, Chief Clinical Officer of Quantum Surgical.
Epione is a robotic-assisted percutaneous ablation system, using a robotic arm, a navigation system and a camera.
This procedure is an alternative to surgery in which a needle is inserted through the skin to the tumor to destroy it. This technique makes it possible to treat tumors that are particularly difficult to reach, due to their size or their location.
Relying on the know-how of the practitioner, Epione integrates all the steps of a percutaneous ablation procedure in a single platform: planning, targeting, ablation, confirmation.
Source: Company Press Release